IDiyas

For the Inventor, By the Inventor

Basel, Switzerland

Rudolf Pfister

USPTO Granted Patents = 17

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 131(Granted Patents)


Company Filing History:

goldMedal15 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents
silverMedal2 out of 6,850 
 
Ciba-geigy Corporation
 patents

Years Active: 1978-1987

Loading Chart...
17 patents (USPTO):Explore Patents
1. 4691040 - Derivatives of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ethanol (1987-09-01),
2. 4544655 - Antiinflammatory, analgesic, and antirheumatic (1985-10-01),
3. 4513002 - Cycloheptene derivatives (1985-04-23),
4. 4448991 - Cyclohexene derivatives (1984-05-15),
5. 4348519 - Thiazine derivatives (1982-09-07),
6. 4336268 - Cyclohexene derivative analgesics (1982-06-22),
7. 4269788 - Phenyl-cyclohexadiene-alkylamine derivatives (1981-05-26),
8. 4224445 - Thienothiazine derivatives (1980-09-23),
9. 4187303 - Thiazine derivatives (1980-02-05),
10. 4180662 - Thiazine derivatives (1979-12-25),
11. 4177193 - Thienothiazine derivatives (1979-12-04),
12. 4175085 - Thienothiazine derivatives (1979-11-20),
13. 4173577 - Phenylacetohydroxamic acids (1979-11-06),
14. 4134898 - N-Carbalkoxymethylsulfamoyl thiophene carboxylic acid alkyl esters (1979-01-16),
15. 4092430 - Antiphlogistic phenylacetohydroxamic acid compositions (1978-05-30),

Title: The Innovations of Rudolf Pfister - A Pioneer in Pharmacological Patents

Introduction

Rudolf Pfister, an accomplished inventor based in Basel, Switzerland, has made significant contributions to the field of pharmaceuticals through his innovative inventions. With a remarkable portfolio of 17 patents, Pfister's work primarily focuses on compounds with therapeutic properties, particularly in addressing allergic reactions and inflammatory conditions.

Latest Patents

Among his latest patents is a compound known as derivatives of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ethanol, specifically 1-[2-(4,5,10,11-Tetrahydro-1H-dibenzo[a,d]cyclohepten-5-yl)ethyl]pyrrolidine and its pharmaceutically acceptable acid addition salts. These compounds have demonstrated valuable histamine-H1 antagonistic properties, making them suitable for controlling or preventing allergic reactions such as urticaria, hay fever, anaphylaxis, and over-sensitivity to medications.

Additionally, Pfister has developed another patent for a compound known as 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-6-trifluoromethyl-2H-thieno[2,3-e]-1,2-thiazine 1,1-dioxide and its pharmaceutically acceptable salts. These compounds have showcased significant pharmacodynamic properties, particularly anti-inflammatory, analgesic, and antirheumatic activities, and can be synthesized by reacting a corresponding alkyl ester with 2-aminopyridine, followed by optional salt formation.

Career Highlights

Rudolf Pfister's career spans notable tenures at prominent companies, including Hoffmann-La Roche Inc. and Ciba-Geigy Corporation. His work at these organizations has been instrumental in advancing pharmaceutical research and development, culminating in a plethora of patents that address critical health issues.

Collaborations

Throughout his career, Pfister has collaborated with esteemed colleagues such as Paul Zeller and Dieter Binder. These partnerships have further fueled innovation and contributed to the development of groundbreaking therapeutic compounds.

Conclusion

Rudolf Pfister stands out as a key figure in the realm of pharmaceutical inventions. His work has not only advanced scientific knowledge but also provided invaluable solutions for patients suffering from various ailments. With continued dedication to research and innovation, Pfister's contributions will undoubtedly leave a lasting impact on the field of pharmacology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…